The groundbreaking success of the copyright undeniably reshaped the medication landscape, but investing in companies strongly reliant on generic versions presents a uncertain picture. While early earnings were substantial, the expiration of patents and the rise of cheaper alternatives have eroded market share. Thus, a thorough assessment of ongoing